Foxo3
We are developing a new RNA-based treatment to target a key longevity gene, aiming to stop the tissue damage behind chronic back pain and offer a safer, longer-lasting solution.
Community Sentiment
How do you feel about this ipt?
Project
Market Overview
Summary
We’re creating an RNA therapy to activate a longevity gene, aiming to prevent tissue damage in chronic back pain and provide a safer, longer-lasting treatment for better health as we age.
Problem
Lower back pain, mainly caused by disc degeneration, is a leading cause of disability with few effective treatments. Targeting the FOXO3 gene could offer a new, disease-modifying approach to improve health and longevity.
Impact
This project pioneers precise, safe oligonucleotide drugs to rebalance FOXO3 isoforms, offering the first disease-modifying therapy for degenerative disc disease and unlocking new possibilities for treating age-related conditions.
Market Overview
Summary
We’re creating an RNA therapy to activate a longevity gene, aiming to prevent tissue damage in chronic back pain and provide a safer, longer-lasting treatment for better health as we age.
Problem
Lower back pain, mainly caused by disc degeneration, is a leading cause of disability with few effective treatments. Targeting the FOXO3 gene could offer a new, disease-modifying approach to improve health and longevity.
Impact
This project pioneers precise, safe oligonucleotide drugs to rebalance FOXO3 isoforms, offering the first disease-modifying therapy for degenerative disc disease and unlocking new possibilities for treating age-related conditions.
The project captures value by advancing drug development beyond its initial phase, seeking additional funding through both Web3 mechanisms and traditional biotech investment channels. This approach enables continued research and development, with the goal of achieving revenue through mergers and acquisitions or direct commercialization.
The project's token serves as a governance tool, empowering holders to influence strategic decisions and the management of scientific intellectual property. Any financial returns generated from IP rights are directed to the project treasury, where token holders collectively determine their allocation, ensuring that value created by the project benefits its engaged community.
Lorna Harries
Professor of Molecular Genetics at the College of Medicine and Health, University of Exeter. Her current work focuses on the role of alternative messenger RNA processing and small RNA regulation of genes involved in ageing and common chronic disease. Lorna focuses on the discovery of novel drug targets for age-related disease. She is evaluating novel small molecule and genetic interventions for moderation of splicing regulators and patterns of alternative splicing for efficacy as future anti-degenerative drugs. With her work, Lorna shows and agrees: “Age should be just a number”
Oligo design and demonstration of impact on FOXO3 splicing patterns in fibroblasts
AON Design and Validation in Monolayer Culture in NP and AP cells
Milestone 1a
Assessment of senescence parameters in NP and AP cells
Evaluate AON Efficacy in 2D Culture
Milestone 1b
Optimisation of organ-on-a chip technology
Application of OOC technology and demonstration of baseline senescence parameters
Application of OOC technology and demonstration of functional parameters
Evaluate AON Efficacy in a Human ex vivo Model
Milestone 2
FOXO3 Regulates the Progress and Development of Aging and Aging-Related Diseases.
https://www.eurekaselect.com/article/126982
Extreme longevity variants at the FOXO3 locus may moderate FOXO3 isoform levels
https://link.springer.com/article/10.1007/s11357-021-00431-0
FOXO are required for intervertebral disk homeostasis during aging and their deficiency promotes disk degeneration
https://onlinelibrary.wiley.com/doi/10.1111/acel.12800
FOXO3a overexpression ameliorates intervertebral disc degeneration by decreasing NLRP3-mediated pyroptosis
https://ouci.dntb.gov.ua/en/works/l16Lno59/
Community
Stay up to date
Get the latest community updates and find out about upcoming Foxo3 developments
